In this issue:
IFN-α: best antiviral strategy in HDV infection?
DAAT efficacy differs by race & ethnicity
Short-duration DAAT: high efficacy, even in GT3 HCV
Long-term antiviral therapy reduces HBV cccDNA
Interpreting clinical significance of serum HBsAg levels
HDV-associated mortality in HIV/HBV co-infection
Targeted vs universal therapy: impacts on HCV-related morbidity/mortality
When to initiate HCC surveillance in chronic non-cirrhotic HBV?
Occult HCV infection, despite SVR12 to DAAT post-liver transplantation
Elbasvir + grazoprevir in GT1/4 HCV: NS5A polymorphisms lower SVR12 rates
Please login below to download this issue (PDF)